Acute Leukemias - Republican Scientific Medical Library
Acute Leukemias - Republican Scientific Medical Library
Acute Leukemias - Republican Scientific Medical Library
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
234 Chapter 18 · The Role of Autologous Stem Cell Transplantation in the Management of <strong>Acute</strong> Lymphoblastic Leukemia in Adults<br />
ALL patients received an autologous transplant in CR1<br />
at the Royal Marsden Hospital. The preparative regimen<br />
consisted of melphalan and total body irradiation until<br />
December 1992; subsequently, patients received highdose<br />
melphalan alone. Patients were scheduled to receive<br />
6-mercaptopurine (71%), methotrexate (57%),<br />
and/or vincristine and prednisone (38%) for 2 years<br />
after the transplant. The median time to relapse posttransplant<br />
was 13 months. The cumulative incidence of<br />
relapse at 10 years was 42% (95% CI, 31–55%). The 10year<br />
probability of DFS was 50% (95% CI, 38–62%).<br />
Age > 30 years, longer than 4 weeks to attain CR, and<br />
high risk karyotype [t(9;22)(q34;q11) and t(4;11)<br />
(q21;q23)] were adverse features. Risk stratification<br />
using these features identified three prognostic risk<br />
groups with 0 (47%), 1 (36%), or 2 (17%) adverse features.<br />
The respective 10-year cumulative incidences of<br />
relapse were 20, 48, and 85% (p < 0.001), and the probabilities<br />
of DFS were 72, 41, and 10% (p = 0.003). Patients<br />
who received two or three maintenance drugs<br />
had a lower relapse rate than those who received only<br />
0 or 1. Posttransplant maintenance therapy offered a<br />
benefit for low and standard risk patients, but not those<br />
with high-risk disease [42].<br />
18.5.2 Targeted Therapies: Imatinib Mesylate<br />
The most exciting recent development in the treatment<br />
of the t(9;22)(q34;q11), Ph+ subtype of ALL has been the<br />
promising early results observed with imatinib, a molecule<br />
specifically targeted to the BCR/ABL tyrosine kinase<br />
that is overexpressed as a result of the t(9;22)<br />
(q34;q11) in CML and Ph+ ALL. Imatinib is a specific inhibitor<br />
of the abl protein tyrosine kinase that has demonstrated<br />
remarkable targeted therapeutic efficacy in<br />
patients with the CML and ALL with increased bcr/abl<br />
activity [43]. The Cancer and Leukemia Group B<br />
(CALGB), in combination with the Southwest Oncology<br />
Group (SWOG) have recently initiated a Phase II trial of<br />
sequential chemotherapy, imatinib, and allogeneic or<br />
auto-SCT for adults with newly diagnosed Ph+ ALL.<br />
The primary objectives of this study will be to determine<br />
the ability of imatinib to produce a complete molecular<br />
response following sequential chemotherapy,<br />
imatinib, and transplantation, and to determine the<br />
ability of imatinib to prolong DFS and OS in this<br />
high-risk group of patients. The ongoing ECOG2993/<br />
UKALL 12 protocol for Ph+ ALL patients follows a sim-<br />
ilar strategy [44]. The results of these trials are eagerly<br />
anticipated.<br />
18.5.3 Immunotherapy<br />
In an attempt to induce an immunological response<br />
similar to GVL in allogeneic SCT, immunomodulators,<br />
such as interleukin-2 (IL-2), have been tried without<br />
success in the autologous SCT setting. Blaise, et al. conducted<br />
a prospective, randomized study to investigate<br />
the efficacy of IL-2 after autologous BMT for acute leukemia<br />
in CR1. One hundred thirty patients were enrolled<br />
(ALL, n=52). Analysis was based on an intent<br />
to treat, and 59% of patients randomized to IL-2 started<br />
the drug after a median of 68 days post transplant, and<br />
received 77% of the scheduled dose. With a median follow-up<br />
of 7 years, OS and LFS were not statistically different<br />
between the two study groups [45].<br />
In vivo and ex vivo purging with MoAbs directed<br />
against surface antigens expressed by leukemic blasts,<br />
such as CD20 and CD52, are underway in many clinical<br />
trials, and results are eagerly anticipated.<br />
Finally, active immunotherapy using dendritic cells<br />
(DCs) loaded with tumor-associated antigens to induce<br />
specific T-cell immunity is a potentially effective<br />
approach that is still in early development. Rijke, et al.<br />
investigated the use of HB-1 antigen as an autologous<br />
T-cell vaccine target, based on their previous studies<br />
that indicated HB-1 is a B-cell lineage-specific antigen<br />
that is recognized by donor-derived cytotoxic T lymphocytes<br />
(CTLs) on allogeneic B-ALL tumor cells. They<br />
demonstrated that HB-1 induces both helper and cytotoxic<br />
T-cell responses by in vitro studies [46]. This<br />
approach now needs to be evaluated in the in vivo setting.<br />
18.6 Conclusion<br />
In conclusion, transplantation is an effective modality<br />
in the treatment of ALL. In patients with high-risk<br />
ALL, multiple randomized trials have demonstrated<br />
the tremendous therapeutic benefit for early allogeneic<br />
SCT. However, in patients without an appropriate HLA<br />
donor, autologous SCT may be a reasonable approach<br />
to extend DFS for those in remission. The leukemic burden<br />
pretransplant will affect disease outcome, and randomized,<br />
prospective studies are necessary to deter-